Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board (see also Pharmaceutical Companies). Mr. Enyedy joins ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company's Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company's pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. During his tenure at Genzyme, Mr. Enyedy developed and executed the company's strategy to enter the oncology market, overseeing the launch of two new products and managing a global business generating over $675 million in revenue with operations in more than 50 countries. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law Schooland a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Fate Therapeutics.